Lyn peptide inhibitor TFA 

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders^[1].

Lyn peptide inhibitor (20 μM; 2 h) TFA specifically blocks the binding of Lyn kinase to the βc subunit of IL-5/GM-CSF receptor in purified human eosinophils, without altering the binding of Jak2 to βc^[1].
Lyn peptide inhibitor (5-20 μM; 2 h) TFA dose-dependently blocks IL-5-induced cellular protein tyrosine phosphorylation and Lyn kinase activation in purified human eosinophils, without inhibiting Jak2 kinase activation^[1].
N-stearoylated Lyn peptide inhibitor (20 μM; 2 h) TFA blocks IL-5/IL-3-induced differentiation of mouse bone marrow cells into eosinophils. A significant inhibitory effect is observed on day 3 of culture, and this inhibitory effect persists until day 10 of culture^[1]
N-stearoylated Lyn peptide inhibitor (2-20 μM; 2 h) TFA reduces IL-5-induced viability of purified human eosinophils in a dose-dependent manner, with significant decreases in cell viability observed at concentrations of 10 μM and 20 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

The Lyn peptide inhibitor (2 mmol (≈0.5 mg); intrabronchial; single dose) TFA significantly reduces allergen-induced airway eosinophil influx in a murine asthma model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2370.88 (free base)

C₁₁₅H₁₈₄N₃₀O₂₄.xC₂HF₃O₂

{Stearoyl}-Tyr-Gly-Tyr-Arg-Leu-Arg-Arg-Lys-Trp-Glu-Glu-Lys-Ile-Pro-Asn-Pro-NH2

{Stearoyl}-YGYRLRRKWEEKIPNP-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. T Adachi, et al. The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. J Immunol. 1999 Feb 1;162(3):1496-501.  [Content Brief]

  [2]. T Adachi, et al. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol. 1999 Jul 15;163(2):939-46.  [Content Brief]